New York State Common Retirement Fund Biotechnology

New York State Common Retirement Fund

$73.9 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$107B	$167 Million 0.23% of portfolio	359,479	Q3 2024 Reduced 7.48%
REGN Regeneron Pharmaceuticals, Inc.	$74.3B	$144 Million 0.2% of portfolio	137,386	Q3 2024 Reduced 6.51%
ARGX Argenx Se	$36.5B	$56.7 Million 0.08% of portfolio	104,534	Q3 2024 Reduced 12.88%
HALO Halozyme Therapeutics, Inc.	$7.71B	$44 Million 0.06% of portfolio	769,504	Q3 2024 Reduced 19.59%
TECH Bio Techne Corp	$2.98B	$41.7 Million 0.06% of portfolio	521,913	Q3 2024 Reduced 22.02%
VCEL Vericel Corp	$2.66B	$36.4 Million 0.05% of portfolio	862,664	Q3 2024 Reduced 21.12%
MRNA Moderna, Inc.	$13.2B	$26.8 Million 0.04% of portfolio	400,732	Q3 2024 Reduced 4.76%
ASND Ascendis Pharma A/S	$7.35B	$26.8 Million 0.04% of portfolio	179,318	Q3 2024 Reduced 10.07%
VCYT Veracyte, Inc.	$2.94B	$26.6 Million 0.04% of portfolio	782,860	Q3 2024 Reduced 11.92%
BNTX Bio N Tech Se	$27.4B	$25.9 Million 0.04% of portfolio	218,067	Q3 2024 Added 457.92%
INSM Insmed Inc	$9.86B	$21.4 Million 0.03% of portfolio	292,779	Q3 2024 Reduced 9.16%
ALNY Alnylam Pharmaceuticals, Inc.	$30.7B	$21 Million 0.03% of portfolio	76,228	Q3 2024 Reduced 19.49%
SRPT Sarepta Therapeutics, Inc.	$10.3B	$17 Million 0.02% of portfolio	136,362	Q3 2024 Reduced 13.95%
UTHR United Therapeutics Corp	$16.7B	$13.2 Million 0.02% of portfolio	36,815	Q3 2024 Reduced 13.02%
SWTX Spring Works Therapeutics, Inc.	$2.22B	$11.7 Million 0.02% of portfolio	364,060	Q3 2024 Added 1.88%
IOVA Iovance Biotherapeutics, Inc.	$909M	$11.5 Million 0.02% of portfolio	1,220,257	Q3 2024 Added 0.94%
CDMO Avid Bioservices, Inc.	$770M	$11.2 Million 0.02% of portfolio	985,879	Q3 2024 Added 11.15%
APLS Apellis Pharmaceuticals, Inc.	$3.27B	$10.9 Million 0.01% of portfolio	376,613	Q3 2024 Reduced 12.64%
IDYA Ideaya Biosciences, Inc.	$1.09B	$10.5 Million 0.01% of portfolio	331,072	Q3 2024 Reduced 14.57%
MDGL Madrigal Pharmaceuticals, Inc.	$4.67B	$9.86 Million 0.01% of portfolio	46,445	Q3 2024 Reduced 9.24%
FOLD Amicus Therapeutics, Inc.	$2.63B	$9.8 Million 0.01% of portfolio	917,514	Q3 2024 Reduced 40.85%
NVO Novo Nordisk A S	$188B	$9.37 Million 0.01% of portfolio	78,668	Q3 2024 Reduced 0.59%
MIRM Mirum Pharmaceuticals, Inc.	$1.68B	$8.91 Million 0.01% of portfolio	228,351	Q3 2024 Added 20.11%
LGND Ligand Pharmaceuticals Inc	$1.88B	$8.64 Million 0.01% of portfolio	86,295	Q3 2024 Added 1,075.36%
RNA Avidity Biosciences, Inc.	$1.47B	$8.46 Million 0.01% of portfolio	184,213	Q3 2024 Added 53.04%
IONS Ionis Pharmaceuticals Inc	$4.58B	$7.96 Million 0.01% of portfolio	198,759	Q3 2024 Reduced 7.86%
RPRX Royalty Pharma PLC	$13.5B	$7.93 Million 0.01% of portfolio	280,315	Q3 2024 Reduced 14.42%
VKTX Viking Therapeutics, Inc.	$2.5B	$7.75 Million 0.01% of portfolio	122,398	Q3 2024 Added 107.23%
CRNX Crinetics Pharmaceuticals, Inc.	$1.96B	$7.55 Million 0.01% of portfolio	147,691	Q3 2024 Reduced 11.43%
BMRN Biomarin Pharmaceutical Inc	$11.4B	$6.91 Million 0.01% of portfolio	98,245	Q3 2024 Reduced 67.21%
PCVX Vaxcyte, Inc.	$5.21B	$6.56 Million 0.01% of portfolio	57,381	Q3 2024 Reduced 0.17%
JAZZ Jazz Pharmaceuticals PLC	$7.69B	$6.37 Million 0.01% of portfolio	57,130	Q3 2024 Reduced 13.23%
IMCR Immunocore Holdings PLC	$1.28B	$6.31 Million 0.01% of portfolio	202,806	Q3 2024 Reduced 12.81%
INCY Incyte Corp	$16.1B	$5.69 Million 0.01% of portfolio	86,141	Q3 2024 Reduced 32.67%
XENE Xenon Pharmaceuticals Inc.	$2.47B	$5.22 Million 0.01% of portfolio	132,521	Q3 2024 Reduced 12.14%
ADMA Adma Biologics, Inc.	$3.27B	$5.11 Million 0.01% of portfolio	255,569	Q3 2024 Added 3.18%
KRYS Krystal Biotech, Inc.	$3.72B	$4.71 Million 0.01% of portfolio	25,863	Q3 2024 Reduced 8.87%
EXEL Exelixis, Inc.	$11.8B	$4.56 Million 0.01% of portfolio	175,717	Q3 2024 Reduced 17.78%
DNLI Denali Therapeutics Inc.	$2.91B	$4.37 Million 0.01% of portfolio	149,908	Q3 2024 Reduced 8.56%
RARE Ultragenyx Pharmaceutical Inc.	$2.86B	$3.53 Million 0.0% of portfolio	63,571	Q3 2024 Added 16.17%
RVMD Revolution Medicines, Inc.	$3.5B	$2.56 Million 0.0% of portfolio	56,357	Q3 2024 Reduced 37.01%
HRTX Heron Therapeutics, Inc.	$186M	$2.55 Million 0.0% of portfolio	1,279,944	Q3 2024 Added 2.81%
INVA Innoviva, Inc.	$1.29B	$2.43 Million 0.0% of portfolio	125,892	Q3 2024 Reduced 16.57%
ROIV Roivant Sciences Ltd.	$7.67B	$2.2 Million 0.0% of portfolio	190,793	Q3 2024 Reduced 12.07%
NUVL Nuvalent, Inc.	$3.27B	$1.99 Million 0.0% of portfolio	19,466	Q3 2024 Reduced 32.18%
BGNE Bei Gene, Ltd.	$20.8B	$1.92 Million 0.0% of portfolio	8,569	Q2 2024 Added 44.72%
HRMY Harmony Biosciences Holdings, Inc.	$2.28B	$1.9 Million 0.0% of portfolio	47,472	Q3 2024 Added 168.63%
CORT Corcept Therapeutics Inc	$5.83B	$1.83 Million 0.0% of portfolio	39,425	Q3 2024 Reduced 16.16%
CYTK Cytokinetics Inc	$4.42B	$1.83 Million 0.0% of portfolio	34,567	Q3 2024 Reduced 27.02%
BPMC Blueprint Medicines Corp	$6.21B	$1.81 Million 0.0% of portfolio	19,520	Q3 2024 Reduced 40.3%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.